These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39209965)

  • 1. Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis.
    González-Rodriguez MA; Troutman S; Bayle S; Lester DK; Grove M; Duckett D; Kareta MS; Kissil JL
    Oncogene; 2024 Sep; 43(40):2995-3002. PubMed ID: 39209965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.
    Troutman S; Moleirinho S; Kota S; Nettles K; Fallahi M; Johnson GL; Kissil JL
    Oncotarget; 2016 Aug; 7(34):54515-54525. PubMed ID: 27363027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.
    Kim BH; Chung YH; Woo TG; Kang SM; Park S; Kim M; Park BJ
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
    Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
    Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four distinct ipsilateral vestibular schwannomas: A case of mosaic NF2-related schwannomatosis.
    Tunkel AE; Youner ER; Barseghyan H; Fu Y; Bhattacharya S; Bornhorst M; Monfared AS
    Am J Clin Pathol; 2024 Aug; 162(2):110-114. PubMed ID: 38527168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
    Petrilli A; Bott M; Fernández-Valle C
    Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
    Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
    Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
    Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
    Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
    Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
    Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
    Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromatosis.
    McClatchey AI
    Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
    Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
    Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
    Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
    Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2.
    Doherty J; Mandati V; González Rodriguez MA; Troutman S; Shepard A; Harbaugh D; Brody R; Miller DC; Kareta MS; Kissil JL
    Neurooncol Adv; 2022; 4(1):vdac072. PubMed ID: 35855490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schwannomatosis: a genetic and epidemiological study.
    Evans DG; Bowers NL; Tobi S; Hartley C; Wallace AJ; King AT; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Freeman SR; Ealing J; Kellett M; Laitt R; Thomas O; Halliday D; Ferner R; Taylor A; Duff C; Harkness EF; Smith MJ
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1215-1219. PubMed ID: 29909380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.